Structure Therapeutics Quarterly Cash Flow Statement
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.54-0.13 (-0.51%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Structure Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Structure Therapeutics generated -$120.1 million of operating cash flow and spent $42,000 on capital expenditures. That left free cash flow of -$120.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Structure Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -106.16M | -75.97M | 33.00M | -65.71M | -61.66M | -46.83M | -36.48M | -33.98M | -26.03M | -26.04M | -24.50M | -23.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 551.00K | 576.00K | 412.00K | 356.00K | 291.00K | 274.00K | 273.00K | 265.00K | 232.00K | 222.00K | 72.00K | 79.00K |
| Stock-Based Compensation | 12.63M | 11.64M | 8.07M | 7.50M | 7.51M | 5.92M | 5.83M | 6.02M | 4.20M | 2.74M | 2.10M | 1.86M |
| Change in Working Capital | 6.03M | -12.96M | -14.13M | 6.63M | 218.00K | -4.36M | 249.00K | 8.44M | -1.98M | -4.81M | -352.00K | -3.28M |
| Operating Cash Flow | -120.11M | 15.23M | -64.42M | -51.00M | -54.56M | -52.23M | -36.47M | -19.70M | -26.39M | -34.08M | -21.73M | -20.56M |
| Capital Expenditures | 42.00K | -1.18M | -1.50M | -1.57M | -232.00K | -314.00K | -16.00K | -685.00K | -427.00K | -162.00K | -1.16M | -820.00K |
| Investing Cash Flow | 74.50M | -496.95M | 56.14M | -49.32M | 48.94M | 34.03M | 33.23M | -189.04M | -204.51M | 1.42M | -180.74M | 30.13M |
| Financing Cash Flow | 2.08M | -1.74M | 704.99M | 56.20M | 517.00K | 809.00K | 615.00K | -757.00K | 514.70M | 702.00K | 281.63M | 473.00K |
| Net Change in Cash | -43.53M | -483.45M | 696.71M | -44.11M | -5.10M | -17.39M | -2.62M | -209.50M | 283.80M | -31.96M | 79.16M | 10.04M |
| Free Cash Flow | -120.07M | 14.05M | -65.91M | -52.57M | -54.79M | -52.54M | -36.48M | -20.38M | -26.82M | -34.24M | -22.89M | -21.38M |
This table shows 12 quarterly periods of Structure Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GPCR's reporting calendar. What is a cash flow statement?